Opinion|Videos|April 7, 2025
Monitoring Tumor Heterogeneity and Detecting Resistance
Experts discuss the tools available to monitor tumor heterogeneity and detect resistance, examining the reliability of current testing methods, differences in molecular testing for newly diagnosed metastatic patients vs those who have progressed, the role of liquid biopsy compared to traditional tissue biopsy, and how these test results inform risk assessment and clinical decision-making.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What tools do we currently have to monitor tumor heterogeneity and detect resistance? How reliable are our current testing methods in capturing the complete resistance profile?
- How does molecular testing differ for newly diagnosed metastatic patients vs those who have progressed on prior therapies?
- What role does liquid biopsy play compared to traditional tissue biopsy in detecting heterogeneity?
- How do you incorporate these test results into your risk assessment and clinical decision-making?
Advertisement
Related to this article
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.
Pelareorep plus a checkpoint inhibitor earned FDA fast track designation for pretreated, inoperable, recurrent, or metastatic squamous cell anal carcinoma.
Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.
The IL-10–expressing anti-CD19 CAR T-cell therapy produced a 92.9% complete response rate and a 92.9% 1-year overall survival rate in high-risk relapsed/refractory DLBCL.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 7/12
2
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
3
Five Under 5: Top Oncology Videos for the Week of 7/12
4
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
5